{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:13:08Z","timestamp":1789726388486,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,6,13]],"date-time":"2015-06-13T00:00:00Z","timestamp":1434153600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s40265-015-0420-z","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T04:41:24Z","timestamp":1434084084000},"page":"1141-1152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Exenatide Extended-Release: An Updated Review of Its Use in Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"75","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,13]]},"reference":[{"issue":"1","key":"420_CR1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140\u20139.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"420_CR2","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","volume":"37","author":"American Diabetes Association","year":"2014","unstructured":"American Diabetes Association. Standards of medical care in diabetes: 2014. Diabetes Care. 2014;37(Suppl 1):S14\u201380.","journal-title":"Diabetes Care"},{"issue":"2","key":"420_CR3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4158\/endp.19.2.a38267720403k242","volume":"19","author":"AJ Garber","year":"2013","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm. Endocr Pract. 2013;19(2):327\u201336.","journal-title":"Endocr Pract"},{"issue":"6 Suppl","key":"420_CR4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjmed.2009.03.012","volume":"122","author":"MA Nauck","year":"2009","unstructured":"Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009;122(6 Suppl):S3\u201310.","journal-title":"Am J Med."},{"issue":"3","key":"420_CR5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40265-013-0172-6","volume":"74","author":"PL McCormack","year":"2014","unstructured":"McCormack PL. Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. Drugs. 2014;74(3):325\u201351.","journal-title":"Drugs"},{"issue":"11","key":"420_CR6","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1089\/dia.2011.0050","volume":"13","author":"MB DeYoung","year":"2011","unstructured":"DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145\u201354.","journal-title":"Diabetes Technol Ther"},{"key":"420_CR7","unstructured":"AstraZeneca. Bydureon\u00ae (exenatide extended-release for injectable suspension): US prescribing information. 2012. http:\/\/www.accessdata.fda.gov . Accessed 27 May 2015."},{"key":"420_CR8","unstructured":"LaRue S, Malloy J, Halili RB. Dual-chamber pen design and testing for injection of exenatide dispersed in poly-(D,L-lactide-co-glycolide) microspheres for once-weekly treatment of type 2 diabetes [abstract no. P-257]. In: 7th International Conference on Advanced Technology & Treatments for Diabetes. 2014."},{"key":"420_CR9","unstructured":"European Medicines Agency. Bydureon 2\u00a0mg powder and solvent for prolonged-release suspension for injection: summary of product characteristics. 2011. http:\/\/www.ema.europa.eu . Accessed 27 May 2015."},{"key":"420_CR10","unstructured":"AstraZeneca. US FDA approves Bydureon\u00ae Pen (exenatide extended-release for injectable suspension) for once-weekly treatment of adults with type 2 diabetes [media release]. 3 March 2014. http:\/\/www.astrazeneca.com ."},{"issue":"12","key":"420_CR11","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2165\/11209750-000000000-00000","volume":"72","author":"LJ Scott","year":"2012","unstructured":"Scott LJ. Exenatide extended-release: a review of its use in type 2 diabetes mellitus. Drugs. 2012;72(12):1679\u2013707.","journal-title":"Drugs"},{"issue":"6","key":"420_CR12","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/00003495-200767060-00008","volume":"67","author":"RS Cvetkovic","year":"2007","unstructured":"Cvetkovic RS, Plosker GL. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and\/or a sulfonylurea). Drugs. 2007;67(6):935\u201354.","journal-title":"Drugs"},{"issue":"6","key":"420_CR13","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc06-2375","volume":"30","author":"DM Kim","year":"2007","unstructured":"Kim DM, Macconell LP, Zhuang DP, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care. 2007;30(6):1487\u201393.","journal-title":"Diabetes Care"},{"issue":"8","key":"420_CR14","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1507\/endocrj.K09E-147","volume":"56","author":"K Iwamoto","year":"2009","unstructured":"Iwamoto K, Nasu R, Yamamura A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. Endocr J. 2009;56(8):951\u201362.","journal-title":"Endocr J"},{"issue":"1","key":"420_CR15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.2040-1124.2012.00238.x","volume":"4","author":"L Ji","year":"2013","unstructured":"Ji L, Onishi Y, Ahn CW, et al. Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus. J Diabetes Investig. 2013;4(1):53\u201361.","journal-title":"J Diabetes Investig"},{"issue":"9","key":"420_CR16","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.clinthera.2012.07.007","volume":"34","author":"N Inagaki","year":"2012","unstructured":"Inagaki N, Atsumi Y, Oura T, et al. Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study. Clin Ther. 2012;34(9):1892\u2013908.","journal-title":"Clin Ther"},{"issue":"2","key":"420_CR17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","volume":"35","author":"D Russell-Jones","year":"2012","unstructured":"Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care. 2012;35(2):252\u20138.","journal-title":"Diabetes Care"},{"issue":"9733","key":"420_CR18","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/S0140-6736(10)60406-0","volume":"375","author":"M Diamant","year":"2010","unstructured":"Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234\u201343.","journal-title":"Lancet"},{"issue":"4","key":"420_CR19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/dc11-1233","volume":"35","author":"M Diamant","year":"2012","unstructured":"Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care. 2012;35(4):683\u20139.","journal-title":"Diabetes Care"},{"issue":"4","key":"420_CR20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/j.1365-2125.2012.04416.x","volume":"75","author":"B Darp\u00f6","year":"2013","unstructured":"Darp\u00f6 B, Philip S, MacConell L, et al. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects. Br J Clin Pharmacol. 2013;75(4):979\u201389.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"420_CR21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11585880-000000000-00000","volume":"50","author":"M Fineman","year":"2011","unstructured":"Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011;50(1):65\u201374.","journal-title":"Clin Pharmacokinet"},{"issue":"9645","key":"420_CR22","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240\u201350.","journal-title":"Lancet"},{"issue":"2","key":"420_CR23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/1753-0407.12020","volume":"5","author":"YM Cui","year":"2013","unstructured":"Cui YM, Guo XH, Zhang DM, et al. Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus. J Diabetes. 2013;5(2):127\u201335.","journal-title":"J Diabetes"},{"issue":"5","key":"420_CR24","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","volume":"96","author":"T Blevins","year":"2011","unstructured":"Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301\u201310.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9861","key":"420_CR25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","volume":"381","author":"JB Buse","year":"2013","unstructured":"Buse JB, Nauck M, Forst T, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381(9861):117\u201324.","journal-title":"Lancet"},{"issue":"9739","key":"420_CR26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","volume":"376","author":"RM Bergenstal","year":"2010","unstructured":"Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431\u20139.","journal-title":"Lancet"},{"issue":"5","key":"420_CR27","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.2337\/dc12-1333","volume":"36","author":"M Davies","year":"2013","unstructured":"Davies M, Heller S, Sreenan S, et al. Once-weekly exenatide versus once- or twice-daily insulin detemir. Diabetes Care. 2013;36(5):1368\u201376.","journal-title":"Diabetes Care"},{"issue":"6","key":"420_CR28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(14)70029-4","volume":"2","author":"M Diamant","year":"2014","unstructured":"Diamant M, Van Gaal L, Guerci B, et al. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol. 2014;2(6):464\u201373.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"420_CR29","first-page":"31","volume":"6","author":"L Macconell","year":"2013","unstructured":"Macconell L, Pencek R, Li Y, et al. Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years. Diabetes Metab Syndr Obes. 2013;6:31\u201341.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"420_CR30","unstructured":"Henry RR, Klein EJ, Malloy J, et al. DURATION-1 extension: efficacy and tolerability of exenatide once weekly (QW) over 6\u00a0years in patients with T2DM [abstract no. 964-P]. In: 74th Annual Scientific Sessions of the American Diabetes Association. 2014."},{"issue":"6","key":"420_CR31","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2337\/dc09-1914","volume":"33","author":"JB Buse","year":"2010","unstructured":"Buse JB, Drucker DJ, Taylor KL, et al. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010;33(6):1255\u201361.","journal-title":"Diabetes Care"},{"key":"420_CR32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1472-6823-11-9","volume":"11","author":"K Taylor","year":"2011","unstructured":"Taylor K, Gurney K, Han J, et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2\u00a0years. BMC Endocr Disord. 2011;11:9.","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"420_CR33","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1464-5491.2011.03301.x","volume":"28","author":"C Wysham","year":"2011","unstructured":"Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med. 2011;28(6):705\u201314.","journal-title":"Diabet Med"},{"issue":"3","key":"420_CR34","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.mayocp.2015.01.008","volume":"90","author":"CH Wysham","year":"2015","unstructured":"Wysham CH, MacConell LA, Maggs DG, et al. Five-year efficacy and safety data of exenatide once weekly: long-term results from the randomized, controlled DURATION-1 trial. Mayo Clin Proc. 2015;90(3):356\u201365.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"420_CR35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/dom.12007","volume":"15","author":"DA Scott","year":"2013","unstructured":"Scott DA, Boye KS, Timlin L, et al. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes Obes Metab. 2013;15(3):213\u201323.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"420_CR36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3810\/pgm.2013.09.2704","volume":"125","author":"M Grimm","year":"2013","unstructured":"Grimm M, Li Y, Brunell SC, et al. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control. Postgrad Med. 2013;125(5):101\u20138.","journal-title":"Postgrad Med"},{"issue":"3","key":"420_CR37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3810\/pgm.2013.05.2661","volume":"125","author":"J Malloy","year":"2013","unstructured":"Malloy J, Meloni A, Han J. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data. Postgrad Med. 2013;125(3):58\u201367.","journal-title":"Postgrad Med"},{"issue":"3","key":"420_CR38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3810\/pgm.2013.05.2660","volume":"125","author":"M Grimm","year":"2013","unstructured":"Grimm M, Han J, Weaver C, et al. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. Postgrad Med. 2013;125(3):47\u201357.","journal-title":"Postgrad Med"},{"issue":"10","key":"420_CR39","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.clinthera.2012.09.007","volume":"34","author":"P Norwood","year":"2012","unstructured":"Norwood P, Liutkus JF, Haber H, et al. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2\u00a0years. Clin Ther. 2012;34(10):2082\u201390.","journal-title":"Clin Ther"},{"issue":"Suppl 1","key":"420_CR40","first-page":"A308","volume":"62","author":"L Blonde","year":"2013","unstructured":"Blonde L, Macconell L, Huang W, et al. Exenatide once weekly: association between weight response, glycemic control, and markers of cardiovascular risk [abstract no. 1182-P]. Diabetes. 2013;62(Suppl 1):A308\u20139.","journal-title":"Diabetes"},{"key":"420_CR41","unstructured":"Chilton RJ, MacConell LA, Han JC, et al. Characterization of heart rate increases with glucagon-like peptide-1 agonist therapy [abstract no. A16290]. Circulation. 2013;128(Suppl 2)."},{"issue":"7","key":"420_CR42","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1464-5491.2009.02752.x","volume":"26","author":"JH Best","year":"2009","unstructured":"Best JH, Boye KS, Rubin RR, et al. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. Diabet Med. 2009;26(7):722\u20138.","journal-title":"Diabet Med"},{"issue":"2","key":"420_CR43","doi-asserted-by":"crossref","first-page":"314","DOI":"10.2337\/dc10-1119","volume":"34","author":"JH Best","year":"2011","unstructured":"Best JH, Rubin RR, Peyrot M, et al. Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26\u00a0weeks of treatment. Diabetes Care. 2011;34(2):314\u20139.","journal-title":"Diabetes Care"},{"key":"420_CR44","first-page":"241","volume":"8","author":"L MacConell","year":"2015","unstructured":"MacConell L, Gurney K, Malloy J, et al. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes. 2015;8:241\u201353.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"12","key":"420_CR45","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1463-1326.2012.01639.x","volume":"14","author":"T Ridge","year":"2012","unstructured":"Ridge T, Moretto T, MacConell L, et al. Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14(12):1097\u2013103.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"420_CR46","first-page":"S363","volume":"56","author":"B Cirincione","year":"2013","unstructured":"Cirincione B, Edwards J, Aisporna M, et al. Gastrointestinal tolerability with twice-daily or once-weekly exenatide formulations was not predicted by concentration with long-term treatment [abstract no. 910]. Diabetologia. 2013;56(Suppl 1):S363.","journal-title":"Diabetologia"},{"issue":"2","key":"420_CR47","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.ajkd.2013.03.026","volume":"62","author":"KR Tuttle","year":"2013","unstructured":"Tuttle KR, Heilmann C, Hoogwerf BJ, et al. Effects of exenatide on kidney function, adverse events, and clinical end points of kidney disease in type 2 diabetes. Am J Kidney Dis. 2013;62(2):396\u20138.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"420_CR48","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1463-1326.2012.01561.x","volume":"14","author":"MS Fineman","year":"2012","unstructured":"Fineman MS, Mace KF, Diamant M, et al. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012;14(6):546\u201354.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"420_CR49","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2147\/VHRM.S28744","volume":"8","author":"JA Gaebler","year":"2012","unstructured":"Gaebler JA, Soto-Campos G, Alperin P, et al. Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis. Vasc Health Risk Manag. 2012;8(1):255\u201364.","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"420_CR50","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3111\/13696998.2012.670677","volume":"15","author":"AL Guillermin","year":"2012","unstructured":"Guillermin AL, Lloyd A, Best JH, et al. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. J Med Econ. 2012;15(4):654\u201363.","journal-title":"J Med Econ"},{"issue":"Suppl 2","key":"420_CR51","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3111\/13696998.2012.708691","volume":"15","author":"Y Samyshkin","year":"2012","unstructured":"Samyshkin Y, Guillermin AL, Best JH, et al. Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US. J Med Econ. 2012;15(Suppl 2):6\u201313.","journal-title":"J Med Econ"},{"issue":"7","key":"420_CR52","doi-asserted-by":"crossref","first-page":"926","DOI":"10.3111\/13696998.2013.803110","volume":"16","author":"T Fonseca","year":"2013","unstructured":"Fonseca T, Clegg J, Caputo G, et al. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index \u226530\u00a0kg\/m2 in Spain. J Med Econ. 2013;16(7):926\u201338.","journal-title":"J Med Econ"},{"issue":"11","key":"420_CR53","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s12325-014-0166-0","volume":"31","author":"SS Johnston","year":"2014","unstructured":"Johnston SS, Nguyen H, Felber E, et al. Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther. 2014;31(11):1119\u201333.","journal-title":"Adv Ther"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0420-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0420-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0420-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T15:41:43Z","timestamp":1559490103000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0420-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,13]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["420"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0420-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,13]]}}}